EP Patent

EP3675838A4 — LIPID PRODUCTS DIRECTED TO THE LYMPHATIC SYSTEM

Assigned to Monash University · Expires 2021-04-21 · 5y expired

What this patent protects

Patent listed against ruxolitinib-phosphate.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP3675838A4
Jurisdiction: EP
Classification: —
Expires: 2021-04-21
Drug substance claim: No
Drug product claim: No
Assignee: Monash University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.